Buffergel Abstracts

Abstracts
Microbicide Efficacy Tests in a Mouse Chlamydia Trachomatis Vaginal Challenge Model

BufferGel™ Favors In Vitro Growth of Lactobacilli While Inhibiting BV-Associated Organisms

Tests of BufferGel™ in Animal Models for Contraception and Prevention of Sexually Transmitted Diseases

Treatment of Bacterial Vaginosis with an Acidic Buffering Gel (BufferGel™): Pilot Study

BufferGel™ is an Active Spermicide in the Standard Postcoital Test

Manuscripts
Olmsted SS, Dubin NH, Cone RA, Moench TR. The rate at which human sperm are immobilized and killed by mild acidity.
Fertil. Steril. 2000 73(4):687-693.

Moench TR, Chipato T, Padian NS. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices.
AIDS 2001, 15: 1595-1602.

Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW, Olmsted SS, Whaley KJ, Cone RA, Moench TR. Tests of BufferGel for contraception and prevention of sexually transmitted diseases in animal models. Sexually Transmitted Dis. 2001, 28(7): 417-423

Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin. Infect. Dis. 2001, 32: 476-482.

Vande Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenjo Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K. Phase 1 trial of the topical microbicide BufferGel : safety results from four international sites. J. AIDS 2001, 26: 41-27.